SCHEMBL4470254

SCHEMBL4470254

COc1ccc(Nc2sc(C(=O)c3ccc(-c4ccccn4)s3)c(N)c2C#N)cc1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
MAPT P10636 4/20 0.54
GAA P10253 1/20 0.54
HPGD P15428 2/20 0.52
MAPK1 P28482 2/20 0.52
HTT P42858 2/20 0.52
MELK Q14680 10/20 0.50
POLB P06746 2/20 0.50
LMNA P02545 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALOX12 P18054 1/20 0.48
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484012 0.92 ALDH1A1 (0.56) ALDH1A1MAPTGAAHPGDMAPK1
SCHEMBL4476868 0.85 MAPT (0.57) ALDH1A1MAPTGAAHPGDMAPK1
SCHEMBL4486561 0.84 MELK (0.51) ALDH1A1MAPTGAAHPGDMAPK1
SCHEMBL4466279 0.84 MAPT (0.54) ALDH1A1MAPTGAAHPGDMAPK1
SCHEMBL4480522 0.83 MAPT (0.48) ALDH1A1MAPTGAAHPGDMAPK1
SCHEMBL4470845 0.82 MELK (0.53) ALDH1A1MAPTGAAHPGDMAPK1
SCHEMBL4476839 0.82 MELK (0.70) ALDH1A1MAPTGAAHPGDMAPK1
SCHEMBL4473381 0.82 ALDH1A1 (0.80) ALDH1A1MAPTGAAHPGDMAPK1
SCHEMBL4473291 0.79 MELK (0.47) ALDH1A1MAPTMELKPOLBMEN1
SCHEMBL4474300 0.79 MELK (0.55) ALDH1A1MAPTGAAMELK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A ALDH1A1 802/4885MAPT 3524/4885GAA 77/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A ALDH1A1 802/4885MAPT 3524/4885GAA 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.